Full Press Release Details
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer.
ZYME
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Key Takeaway: Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Price reaction · baseline $8.71 (2024-05-28 close) · hit after-hours · clean, no other ZYME news in the window
day 0 close · peak
-2.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers